Protocol

BMJ Open Defining indicators for disease burden, health outcomes, policies and barriers and facilitators to health services for migrant populations in the Middle East and North African region: a protocol for a suite of systematic reviews

Farah Seedat ⁽¹⁾, ¹ Stella Evangelidou, ² Moudrick Abdellatifi, ³ Oumnia Bouaddi ⁽²⁾, ³ Alba Cuxart-Graell, ² Hassan Edries ⁽¹⁾, ^{4,5} Eman Elafef, ^{4,5} Taha Maatoug, ⁶ Anissa Ouahchi, ⁶ Liv Mathilde Pampiri, ² Anna Deal, ^{1,7} Sara Arias, ² Adel Abdelkhalek, ⁵ Ahmed Hamed Arisha, ⁵ Bouchra Assarag, ⁸ Ibrahim Ahmed Bani, ⁹ Aasmaa Chaoui, ¹⁰ Wafa Chemao-Elfihri, ⁸ Kenza Hassouni ⁽²⁾, ³ Mahmoud Hilali, ^{4,5} Mohamed Khalis ⁽²⁾, ^{3,11} Wejdene Mansour, ⁶ Ali Mtiraoui, ⁶ Kolitha Wickramage, ¹² Dominik Zenner, ¹³ Ana Requena-Mendez ⁽²⁾, ^{2,14} Sally Hargreaves, ¹ MENA Migrant Health Working Group, ² MENA Migrant Health Working Group²

ABSTRACT

Introduction The Middle East and North African (MENA) region is characterised by high and complex migration flows, yet little is known about the health of migrant populations, their levels of underimmunisation and access to healthcare provision. Data are needed to support regional elimination and control targets for key diseases and the design and delivery of programmes to improve health outcomes in these groups. This protocol describes a suite of seven systematic reviews that aim to identify, appraise and synthesise the available evidence on the burden and health outcomes, policies and access (barriers and facilitators) related to these mobile populations in the region.

Methods Seven systematic reviews will cover three questions to explore the: (1) burden and health outcomes, (2) policies and (3) healthcare barriers and facilitators for the following seven disease areas in migrants in the MENA region: tuberculosis, HIV and hepatitis B and C, malaria and neglected tropical diseases, diabetes, mental health, maternal and neonatal health, and vaccine-preventable diseases. We will search electronic databases for studies in any language (year 2000-2023), reference-check relevant publications and cross-check included studies with experts. We will search for grey literature by hand searching key databases and websites (including regional organisations and MoH websites) for country-specific guidelines and talking to our network of experts for local and regional reports and key datasets. We will assess the studies and policies for their quality using appropriate tools. We will meta-analyse the data by disease outcome if they are of sufficient volume and similarity. Where metaanalysis is not possible and where data are on policy or

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Our systematic reviews use explicit, transparent and recommended methodology.
- ⇒ We will apply comprehensive search strategies with no language restrictions and extensive grey literature searching online and through expert government and non-government support.
- ⇒ We have an international team with multidisciplinary expertise on migrant health, diseases, policymaking and methodology.
- $\Rightarrow\,$ Data prior to the year 2000 will be excluded.
- ⇒ Meta-analysis may not be possible due to heterogeneity, and we anticipate that most of the data will come from grey literature.

access, we will narratively synthesise the evidence using summary tables, figures and text.

Dissemination We anticipate disseminating the findings through peer-reviewed publications, conferences and other formats relevant to all stakeholders. We are following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and protocols will be registered on International Prospective Register of Systematic Reviews.

INTRODUCTION

The Middle East and North African (MENA) region is marked by political and economic instability, extended conflict and high and complex migrant flows. Several countries in

To cite: Seedat F, Evangelidou S, Abdellatifi M, *et al.* Defining indicators for disease burden, health outcomes, policies and barriers and facilitators to health services for migrant populations in the Middle East and North African region: a protocol for a suite of systematic reviews. *BMJ Open* 2024;**14**:e083813. doi:10.1136/ bmjopen-2023-083813

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2023-083813).

AR-M and SH contributed equally.

AR-M and SH are joint senior authors.

Received 29 December 2023 Accepted 11 June 2024

Check for updates

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to Dr Sally Hargreaves; shargrea@sgul.ac.uk this region are points of origin, transit and destination for a varied group of migrants. More than 40 million migrants reside in the region,¹ including 12.6 million internally displaced people (IDPs), 2.4 million refugees, 251 800 asylum seekers and 370 300 stateless persons at the end of 2022.² Mass displacement in Sudan and Palestine have intensified the situation, with reports of over 7 million people becoming newly displaced in Sudan (over 1.38 million fleeing to neighbouring countries) while 1.9 million have been internally displaced in Gaza.³⁴

Migrants are a heterogeneous group; while some are resilient throughout the migration cycle, have sufficient access to services in host countries and good health outcomes, others in the region live and work in precarious conditions, and may face individual-level and systemlevel barriers in accessing healthcare.^{5–7} Efforts have been made to include migrants in national health programmes and enable them access to affordable, acceptable, culturally sensitive and good quality healthcare. For example, Morocco has multisectoral programmes through a national immigration and asylum strategy since 2013 to improve the health and well-being of all migrants, which includes the right of access to free or low-cost essential healthcare under the same conditions as Moroccans.^{8 9} However, migrants may still face economic barriers such as the cost of medication and complimentary tests, which may not be covered, as well as language and cultural barriers, a fear of deportation, racism and discrimination.⁶¹⁰ Non-governmental organisations (NGOs) and United Nations (UN) agencies attempt to close the gap in healthcare provision, but these services often remain insufficient.^{7 11} This context can leave some migrant groups disproportionately affected by various health conditions, with poor morbidity and mortality outcomes.¹²

Globally, it is reported that certain migrant categories may encounter infectious diseases such as tuberculosis (TB) and HIV/AIDS along their journey and in their host countries, and they may be at risk of malaria and neglected tropical diseases (NTDs) for which health professionals may be unfamiliar. There is also evidence that they are disproportionately affected by the burden and consequences of COVID-19.13 Likewise, some migrants, especially refugees and asylum seekers, can be at risk of non-communicable diseases (NCDs), which are often diagnosed late and can be causes of premature mortality.^{7 12 13} In addition, depending on their lived experiences during the migratory trajectory and the contextual factors in the host country, some migrants may suffer adverse mental health outcomes.¹³ Refugee and migrant women tend to have less access to maternal and child health services and are at a higher risk of negative outcomes during pregnancy and delivery than women in host populations.¹³ Migrants are also considered to be an underimmunised group, missing vaccines, doses and boosters as children and adolescents because of their mobility, with WHO calling for greater emphasis to be placed on vaccination across the life course in marginalised groups.¹⁴¹⁵

There is a paucity of data mapping the burden of diseases and underimmunisation in migrants in the MENA region¹³; however, some small studies in some countries suggest that migrants may be at higher risk for some diseases. For example, in Lebanon, migrants are considered a vulnerable group for HIV as the political and economic situation has led to an increase in high-risk behaviours,¹⁶ while cross-border mobile populations in the ports of the Red Sea and adjacent transport corridors are found to be at a higher risk of HIV transmission in the Horn of Africa and Arabian Peninsula.¹⁷ Similarly, high rates of hepatitis B and C have been found in newly arriving sub-Saharan migrants in Libya (23.4% and 31.2%, respectively),¹⁸ and migration has been identified as partly explaining the slowing of the decline in TB and the reintroduction of malaria in the region,^{19 20} as well as outbreaks of neglected tropical diseases such as leishmaniasis and cysticercosis/taeniasis in Lebanon.²¹

The evidence on NCDs is similar. A scoping review in 2019 on Syrian refugees found only two studies that were investigating prevalence-one in Lebanon and one in Jordan.²² The studies found that almost one in two households had a member with an NCD; the two most common NCDs were hypertension and type 2 diabetes mellitus. In Lebanon, the proportion of NCDs was higher in the refugees than the host community (60.2% vs 50.4%, respectively). A retrospective study in Qatar similarly found that diabetes and hypertension were higher in migrants who had just arrived (<6 months) compared with longer durations.²³ There is also some evidence of a high burden of psychiatric disorders, such as generalised anxiety disorder and post-traumatic stress disorder in Lebanon, Sudan and Egypt among refugees and IDPs with premigration exposure to armed conflict.²⁴ The Gulf Cooperation Council reported high rates of psychosis and suicide among migrant domestic workers coming from Indian Subcontinent and South East Asia.²⁵ With respect to maternal and neonatal conditions, a study in Lebanon found that the odds of very preterm birth and other serious antenatal complications were higher for most migrant women compared with host women.²⁶

There is equally little information on the policies and interventions (eg, screening, diagnostic, treatment or vaccination services) available to migrants in the MENA region. Indeed, when exploring the NCD policies for urban refugees, a scoping review in 2020 concluded that there is a scarcity of research on national policy, the prevention of NCDs and the perspective of refugees.²⁷ Likewise, there are little comprehensive data about infectious disease policies among migrants in the MENA region. Two Sudanese studies reported a low vaccination coverage among migrant and internally displaced children against major vaccine-preventable diseases (VPDs).^{28 29} In countries such as Egypt, Iraq, Jordan, Lebanon, Morocco and Tunisia, migrants are included in vaccination policy irrespective of their residency status. However, in some countries, some groups of migrants often cannot access




Figure 1 Schematic illustration of the Migrant Health Country Profile Tool (MHCP-t). NTD, neglected tropical diseases; TB, tuberculosis.

sufficient vaccinations, and NGOs are left to fill this gap, especially for irregular migrants.¹⁴

The lack of comprehensive data on the burden of diseases among migrants in the MENA region makes it difficult to respond to the unmet healthcare needs of the migrant population.^{1 30} Likewise, the extent to which migrants are included in national policies and the barriers they may face could undermine the goals to achieve the legal and human right of universal health coverage, ensure health security for all, and eliminate some of these diseases. Efforts are underway to make integrated migrant health information systems a reality in the MENA region. Since 2015, the International Organization for Migration (IOM) has steered projects fostering health and protection to vulnerable migrants transiting through Morocco, Tunisia, Egypt, Libya, Yemen and more recently, Sudan.³¹ The current phase aims to steer the development of a migrant health country profile tool (MHCP-t) for the region, an innovative digital mechanism to source country-level data on health indicators, health policies and healthcare access across multiple communicable and NCD areas. The MHCP-t will enable a systematic assessment of disease impact on migrants and identify country-level hotspots and gaps in prevention efforts by integrating information from routine health data, registries, surveillance programmes, humanitarian stakeholders and civil society, on health aspects of migrant populations (see figure 1).

A preliminary step in the development of the MHCP-t is to map out the state of the evidence on migrant health data and policies in the MENA region and to inform the development of key indicators for disease burden and health outcomes, policies and access for all relevant disease areas of the MHCP-t. We will also conduct qualitative field studies with migrants, community leaders and healthcare professionals in Morocco, Tunisia and Egypt to further inform the key indicators. The resulting key indicators will be reviewed by national task groups, brought together by the ministries of health, and international experts. The final list of indicators will be developed into the first version of the tool, which will be piloted within the countries using a mixed-methods process evaluation.

To date, there have been no attempts to systematically synthesise the disease, policy or access indicators in the literature about key diseases among migrant populations in the MENA region. This suite of systematic reviews will aim to systematically identify, appraise and synthesise the empirical evidence on key diseases among migrant populations in the MENA.

Research questions and objectives

There are three overarching research questions that will be addressed in seven systematic reviews on seven disease areas to comprehensively map the state of the evidence of migrant health in the MENA region: (1) TB, (2) HIV and hepatitis B and C, (3) malaria and NTDs, (4) diabetes, (5) mental health, (6) maternal and neonatal health and (7) VPDs.

1. What data are available on the disease indicators related to each disease area in migrant populations in the MENA region?

Objectives:

a. Synthesise and appraise data on the burden (eg, prevalence or incidence) of TB, HIV, hepatitis B and C, malaria, NTDs, diabetes, mental health, maternal and neonatal health conditions, and VPDs in migrant populations in the MENA region.

- b. Synthesise and appraise data on intervention outcomes (eg, uptake and coverage of vaccination, screening or treatment, treatment success) related to TB, HIV, hepatitis B and C, malaria, NTDs, diabetes, mental health, maternal and neonatal health, and VPDs in migrant populations in the MENA region.
- c. Synthesise and appraise data on the intermediate (eg, symptoms, severity, or prognosis/long-term morbidity of disease) and final (eg, mortality, quality of life) health outcomes of TB, HIV, hepatitis B and C, malaria, NTDs, diabetes, mental health, maternal and neonatal health conditions, and VPDs in migrant populations in the MENA region.

2. What is the policy response for each disease area related to migrant populations in the MENA region?

- Objective:
- a. Synthesise and appraise the prevention and/or treatment policies for TB, HIV, hepatitis B and C, malaria, NTDs, diabetes, mental health, maternal and neonatal health and VPDs in migrant populations in the MENA region.

3. What are the barriers and facilitators in accessing health services for each disease area for migrant populations in the MENA region?

Objective:

a. Synthesise and appraise the evidence on the barriers and facilitators for accessing prevention and/or treatment services for TB, HIV, hepatitis B and C, malaria, NTDs, diabetes, mental health, maternal and neonatal health and VPDs in migrant populations in the MENA region.

We will disaggregate by, and investigate potential sources of heterogeneity for, country of study, study period, country of origin, migrant type (ie, labour, asylum seekers, refugee), age and sex, where feasible for all objectives, and cross-compare findings across countries in the MENA region.

METHODS AND ANALYSIS

The seven systematic reviews will be reported according to recommendations from the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRIS-MA-P) 2020 statement.³² We will register the systematic reviews protocols at the International Prospective Register of Systematic Reviews.

Search strategies

Electronic database searches

We will search the following electronic databases to identify peer-reviewed literature: Medline (Ovid); Embase (Embase.com); Web of Science (Clarivate), CINAHL (Ebsco), Index Medicus for the Eastern Mediterranean Region (globalindexmedicus.net) and Qscience (qscience.com). Scoping searches have been undertaken

to inform the development of the search strategies. An iterative procedure was used, with input from all authors including an information scientist, recommended search filters, and previous reviews.^{33–37} The searches are separated for each disease area. They combine three sets of search terms using both free text words in title, abstract or keyword heading word, and MeSH terms through boolean operators OR within each set and then AND to combine the sets. The first set is made up of search terms for migrants, the second set is made up of search terms for each disease area and the third set is made up of search terms for the MENA region. The search strategies are limited to humans and restricted to the year 2000 as migratory flows and disease burden change over time, and we are interested in recent migration flows and recent policies. There is no restriction on language. A copy of the overarching search strategy used in the major databases is provided in table 1, and the strategies specific to each disease area (ie, terms for diseases) are presented in the online supplemental material.

Grey literature searches

We will search various sources to identify literature that has not been published in peer-reviewed journals. First, we will search the reference lists of the final list of included studies at full text as well as systematic reviews that meet our criteria that we have sourced from searches of the electronic databases. Second, we will search international and regional websites related to migration and health, such as the IOM, WHO, UNHCR, Red Cross and other relevant UN bodies, Médecins San Frontières (MSF) and other key regional NGOs, and national websites for each country in the MENA region, particularly ministries of health, for guidelines, policies, reports and unpublished datasets. We will use snowballing methodology and search any relevant websites we find from these initial websites, as necessary. We will report every organisation we search in the write up of the review. Once we have a full list of included papers and websites, we will share this with a panel of country-specific and regional experts to review and identify any further data sources that have not been captured.

Study screening and selection

The eligibility criteria by disease area are summarised separately in the table 2 for disease indicators (question 1) and table 3 for policy (question 2) and access (question 3). For disease indicators (question 1), we will include papers that are on the burden (eg, prevalence or incidence), or intervention (eg, uptake, coverage, or completion of interventions such as screening or treatment) or intermediate and final (eg, symptoms, severity, long-term morbidity, mortality, quality of life) health outcomes for TB, HIV, hepatitis B and C, malaria, NTDs, diabetes, mental health, maternal and neonatal health conditions, and VPDs in migrant populations in the MENA region. For policy-related data (question 2), we will include papers that contain a description of the policies themselves, and

Table 1 Overarching set	earch strategy for all reviews	
1	Migrant	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? Or displacement* or emigrant* or emigration or expat? Or expatriate? Or foreigner* or foreign- born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re-settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf. Or exp Human Migration/ or exp "Emigrants and Immigrants"/ or "Transients and Migrants"/ or Refugees/ or Refugee Camps/
2	Disease	Separate for each strategy (see online supplemental material)
3	Countries	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*). ti,ab,kf.Exp middle east/ Exp Africa, Northern/ exp Middle East / or exp Africa, Northern/
4	Combine for indicators	1 AND 2 AND 3
5	Limit to humans	(animals not humans).sh. 4 not 5
	Limit to 2000	Limit 5 to yr="2000-Current"

for access data (question 3) we will include papers that are on determinants of any usage/underusage, facilitators or barriers in accessing health services for the disease areas in migrant populations in the MENA region. Definitions for migrant and the MENA region are described in figure 2.

For disease areas that concern multiple diseases, we have prioritised those that are of greater concern in the MENA region. We are including the following VPDs: cholera, COVID-19, dengue, diphtheria, hepatitis A, hepatitis B; haemophilus influenza type b, human papillomavirus, influenza, measles, meningococcal diseases, mumps, pertussis, pneumococcal disease, poliomyelitis, rabies, rubella, rotavirus, tetanus, TB, typhoid and varicella. For NTDs, we will include buruli ulcer, dengue and chikungunya, dracunculiasis (Guinea-worm disease), echinococcosis, human African trypanosomiasis (sleeping sickness), leishmaniasis, leprosy (Hansen's disease), lymphatic filariasis, mycetoma, and other deep mycoses, onchocerciasis (river blindness), rabies, scabies and other ectoparasitoses, schistosomiasis, soil-transmitted helminthiases, snakebite envenoming, taeniasis/cysticercosis, trachoma, and yaws and other endemic treponematose. We are including any mental health condition, and for NCDs, we have chosen diabetes for this first stage. In the next stage, we will do a wider systematic review on NCDs in migrant populations in the MENA region, including hypertension, cardiovascular diseases, obesity and chronic kidney disease.

will include studies in which any intervention or exposure is reported, or studies where no intervention is reported if the study is about prevalence or incidence alone. For policy and access data, we will include any health interventions relevant for the disease area. For all questions, we will include studies that have no comparator or any type of comparator (ie, a counterfactual group, control group, reference group for an exposure, different migrant subgroup, or an alternative intervention). For publication type, we will include full texts of observational studies, data from national and regional surveillance systems, and trials for the question on disease indicators, although for trials, we will only extract data from the control group or from baseline characteristics, as appropriate. For access data, we will include full-text papers from observational or qualitative studies, or programme reports. For both questions 1 and 3, we will include systematic and narrative reviews only to search for relevant included studies from these papers. For policy data, we will include fulltext papers from any study design, guideline or policy and programme documentation. We will exclude studies on diagnostic accuracy, cost effectiveness of interventions, case series and case reports, and exclude abstracts, editorials, books or opinions, if there are a sufficient number of other publications. We will have no language exclusions as within our coauthors we have speakers of the MENA region (Arabic, French and English) as well as Spanish;

With respect to interventions, for disease indicators, we

Continued

•	
	BMJ Open: first published as 10.1136/bmjopen-2023-083813 on 13 July 2024. Downloaded from http://bmjop
	13 on 13 July 2024. Downloaded from http://bmjopen.bmj.com/ on
	pen.bmj.com/ on July 16, 2024 by guest. Protected by copyright.

Disease	Participants	Intervention/exposure	Comparators	Outcomes	Study design	Publication and language	Exclusions
Overall	Migrants in living in the MENA region.	None or any as reported by the authors	No intervention, counterfactual or control group (eg, host population), different migrant subgroups, or alternative intervention, as reported by authors	Three categories of outcomes: (1) burden (eg, incidence or prevalence); (2) intervention outcomes (eg, uptake, coverage, completion or success of interventions); (3) intermediate (eg, symptoms or severity of disease, long-term mobidity) and final health outcomes	Cohort studies, cross- sectional studies, case-control studies, trial studies (data will only be extracted from baseline characteristics or the control group as appropriate), systematic or narrative reviews (only to find relevant included	Full-text reports in any language. If an insufficient number of full-text reports are found, we will include abstracts, editorials, letters, consensus statements, or ophinons.	Studies on diagnostic accuracy or cost-effectiveness of interventions. Data on the clinical detectiveness will also not be included; however, relevant baseline or control group data from these studies may be included. Case series and case reports.
TB		For example, latent, and active TB screening, diagnosis, and		Burden (eg, incidence or prevalence of active, latent or	primary sucres), data, No language and reports from national/ restrictions. regional surveillance	no language restrictions.	books, consensus statements, or opinions if there are sufficient full texts.

systems

prevalence of active, latent or MDR TB, etc); (2) intervention coverage of active and latent

outcomes (eg, uptake or TB screening, diagnosis,

For example, latent, and active TB screening, diagnosis, and antibacterial treatment, and

so on.

lost to follow-up, microbiologic

cases, etc); (3) intermediate cases with drug resistance,

cure/successfully treated

treatment completion, cases

TB chemoprophylaxis, or treatment for active TB,

comorbidities, extrapulmonary and final health outcomes (eg,

TB, TB meningitis, mortality, life years, disability-adjusted

quality of life, quality-adjusted

life years, etc, for patients with TB)

Study eligibility criteria for disease indicators (question 1) Table 2

							0
Inte	Intervention/exposure	Comparators	Outcomes	Study design	Publication and language	Exclusions	
For e count count count	For example, antiretroviral therapy, health education, condom prevention, counselling and so on.		Burden (eg, incidence, prevalence, etc, of HIV or hep B and C); (2) intervention outcomes (eg, uptake or coverage of HIV or hep B and C screening and testing, knowledge of results, uptake or coverage of HIV or hep B and C treatment, cases lost to follow-up, treatment success, etc); (3) intermediate and final health outcomes (eg, viral load, comorbidities, disease stage, mortality, quality of iffe, quality- adjusted life years, etc, for patients with HIV or hepatitis B and C)				
For externo ed uccat so on.	For example, chemoprophylaxis, health education, vector control, and so on.		Burden (eg, incidence, prevalence, etc., of malaria or NTDs); (2) intervention outcomes (eg, uptake and coverage of: malaria prevention and treatment- related messages, use of an insecticide-treated net, spraying of IRS, first-line antimalarial treatment, spraying of IRS, first-line antimalarial treatment, spraying of IRS, first-line antimalarial treatment, spraying of IRS, first-line antimalarial treatment, and inal areatment, antimalarial treatment, antimalarial treatment antimalarial treatment, spraying of IRS, first-line and final health outcomes (eg, bindness, anemolgical abnormalities, haemoglobin levels, mortality, quality of life, quality-adjusted life years, disability-adjusted life years,				
Vaccination	lation		Burden (eg, incidence, prevalence, etc., of VPDs); (2) intervention outcomes (eg, uptake or coverage of vaccination); (3) intermediate and final health outcomes (eg, severity, long-term illness, mortality, quality of life, disability-adjusted life years, quality-adjusted life years, for patients with VPDs)				Open acce
						Cor	Continued

BMJ Open: first published as 10.1136/bmjopen-2023-083813 on 13 July 2024. Downloaded from http://bmjopen.bmj.com/ on July 16, 2024 by
.com/ on July 16, 2024 by guest. Protected by copyright.

Exclusions

Publication and language

Study design

screening, or treatments, cases

lost to follow-up, treatment

antenatal screening, newborn

skilled delivery attendance,

antenatal care attendance,

weight, preterm birth, etc); (eg, uptake or coverage of

(2) intervention outcomes

preeclampsia, postpartum

Burden (eg, incidence,

Outcomes

Comparators

For example, antenatal care, postnatal care, and so on.

Intervention/exposure

Participants

Disease

MNM

Continued

Table 2

prevalence, etc, of

haemorrhage, low birth

success, etc); (3) intermediate

and final health outcomes (eg, breathing and feeding delays, cerebral palsy, maternal

difficulties, vision or hearing

problems, developmental

mortality, neonatal mortality, disability-adjusted life years,

stillbirth, quality of life,

quality-adjusted life years, etc,

for mothers or newborns with

health conditions)

prevalence, etc. of type I and

support, insulin injections, and

so on.

For example, educational

Diabetes

Burden (eg, incidence,

II diabetes); (2) Intervention

stroke, neuropathy, mortality,

final health outcomes (eg, retinopathy, heart attacks, adjusted life years, quality-

quality of life, disability-

adjusted life years, etc, for

patients with diabetes)

diabetes, loss to follow-up,

etc); (3) Intermediate and

screening, or treatment for

prevention programmes,

and coverage of diabetes

outcomes (eg, uptake

Continued

Table 2 Continued	ntinued						
Disease	Participants	Intervention/exposure	Comparators	Outcomes	Study design	Publication and language	Exclusions
Mental health		For example, psychiatric care, community mental health programmes, MHPSS response, and so on.		Burden (eg, incidence, prevalence, etc, of any mental health conditions); (2) intervention outcomes (eg, uptake and coverage of primary prevention, screening, talking therapy, psychiatric treatment, loss to follow- up, treatment success, etc); (3) intermediate or final health outcomes (eg, stage of condition, functioning, development capabilities, mortality, quality of life, disability-adjusted life years, etc, for patients with mental health conditions)			
Hep, hepatitis; IRS tuberculosis; VPD,	Hep, hepatitis; IRS, Indoor residual spraying; MC tuberculosis; VPD, vaccine-preventable disease.	Hep, hepatitis; IRS, Indoor residual spraying; MDR, multidrug resistant; MENA, Middle East and North Africa; MHPSS, Mental Health and Psychosocial Support; MNH, maternal and neonatal health; NTD, neglected tropical diseases; TB, tuberculosis; VPD, vaccine-preventable disease.	ddle East and North Africa; MH	PSS, Mental Health and Psychosocia	l Support; MNH, maternal and ne	oonatal health; NTD, negle	cted tropical diseases; TB,

if we find an article in another language, we will use a professional translator or an online automated translation service, depending on the cost and budget.

Identified references will be downloaded to bibliographic management software, Rayyan, and deduplicated. Two reviewers will independently screen the titles and abstracts of all identified records (screening level I). Full-text reports of all potentially relevant records identified at screening level I will be obtained and assessed independently by two reviewers using the same study eligibility criteria (screening level II). Any disagreements over inclusion/exclusion at screening level I and II will be resolved by discussion between the two reviewers, with the involvement of a third reviewer if necessary. We will document the study flow and reasons for exclusion of full-text papers in a PRISMA study flow diagram (see online supplemental material).

Data extraction

Two reviewers will independently extract relevant data using an a priori defined extraction sheet that will be piloted and refined before implementation. Data extracted will be cross-checked and any disagreements will be resolved by discussion, with the involvement of a third reviewer if necessary.

Data extracted for disease indicators (question 1) will include study (eg, author, country, publication year, design, setting, sample size, follow-up duration), participant (eg, type of migrant and definition used, country of origin, time in the country, sociodemographic characteristics, living situation (camp setting, community), study eligibility criteria), health or disease indicators including their definitions (eg, description of the intervention if it is about testing or education or treatment), the outcome measures (eg, frequency, percentages, 95% CIs, etc), results reported for each outcome, and any adjustment conducted for confounding of the outcomes. From each study that has adjusted and unadjusted analyses, we will prioritise the adjusted analysis if data allow. Any missing statistical parameters of importance and variability measures (eg, 95% CIs) will be estimated, if data permit. All calculated or derived data will be denoted as 'calculated' and will be incorporated in the extraction sheets.

Data extracted on policies (question 2) will include publication (eg, author, country, publication year, publication type), population covered by policy (eg, type of migrant and definition used, sociodemographic characteristics), summary of interventions covered by policy (and comparators (if appropriate), setting (eg, camp, community), summary of policy, level of authority ((national, regional, local) implementation (legal, recommendation, guideline) and methods used to inform policy. Data extracted on access (question 3) will include study (eg, author, country, publication year, design, setting, sample size, follow-up duration), participant (eg, type of migrant and definition used, country of origin, time in the country, sociodemographic characteristics, living situation (camp setting, community),

Disease Participants Question 2. Policy indicators TB Migrants in th MENA region HIV Hep B and C	Participants y indicators Migrants in the MENA region	Intervention/ exposure Policies for health services related to TB Policies for health	Comparators No intervention, counterfactual or control group (eg, host population), different migrant subgroups, or alternative intervention, as	Outcomes Description of the policy itself	Study design Any study design, guideline, reports, policy or programme information.	Publication and language Exclusions Full-text reports in anv language. Studies on diagnostic	Exclusions
Question 2. Policy indica Question 2. Policy indica HIV Hep B and C	ators ts in the region	Policies for health services related to TB Policies for health	No intervention, counterfactual or control group (eg, host population), different migrant subgroups, or alternative intervention, as	Description of the policy itself	Any study design, guideline, reports, policy or programme information.	Full-text reports in anv language.	Ctudios on diamontia
TB Migrant HIV Hep B and C	ts in the region	Policies for health services related to TB Policies for health	No intervention, counterfactual or control group (eg, host population), different migrant subgroups, or alternative intervention, as	Description of the policy itself	Any study design, guideline, reports, policy or programme information.	Full-text reports in anv language.	Ctudioc on diognoctio
HIV Hep B and C		Policies for health	host population), different migrant subgroups, or alternative intervention, as		information.	No language	accuracy, clinical effectiveness or
Mologio NITDo		services related to HIV and hep B and C	Intervention, as			restrictions.	cost-effectiveness of interventions Case series and case reports
		Policies for health services related to malaria and NTDs	reported by authors				Abstracts, editorials, letters, books or opinions if there are sufficient full texts.
VPDs		Policies related to vaccination					
HNM		Policies for health services related to maternal and neonatal health					
Diabetes		Policies for health services related to diabetes					
Mental health		Policies for health services related to mental health					
Question 3. Access indicators	cators						Continued

Table 3 Continued	inued						
		Intervention/				Publication and	
Disease	Participants	exposure	Comparators	Outcomes	Study design	language	Exclusions
TB	Migrants in the MENA region	Health services related to TB	No intervention, counterfactual or	Barriers Facilitators	Cohort studies, cross-sectional	Full-text reports in any language.	Full-text reports in Studies on diagnostic any language. accuracy, clinical
HIV Hep B and C		Health services related to HIV and hep B and C	control group (eg, host population), different migrant	Determinants of any usage/underusage	Determinants of any studies, case-control usage/underusage studies, descriptive studies, qualitative	No language restrictions.	effectiveness or cost-effectiveness of interventions
Malaria NTDs		Health services related to malaria and NTDs	subgroups, or alternative intervention, as reported by authors		or narrative reviews (only to find relevant included primary		case series and case reports. Abstracts, editorials, letters, books or opinions
VPDs		Vaccination			studies), reports from		if there are sufficient full
HNM		Health services related to maternal and neonatal health			national/regional programmes		texts.
Diabetes		Health services related to diabetes					
Mental health		Health services related to mental health					
Hep, hepatitis; M	IENA, Middle East and I	Vorth Africa; MNH, mate	rnal and neonatal health; I	NTD, neglected tropical	Hep, hepatitis; MENA, Middle East and North Africa; MNH, maternal and neonatal health; NTD, neglected tropical diseases; TB, tuberculosis; VPD, vaccine-preventable disease.	s; VPD, vaccine-prevent	able disease.

Æ	 "An umbrella term, not defined under international lay understanding of a person wher place of usual residence, whether with international border, temporarily or permeasons. The term includes a number of well-defir such as migrant workers; persons whose are legally-defined, such as smuggled mig status or means of movement are not spinternational law, such as international status 	who moves away from his or thin a country or across an nanently, and for a variety of ned legal categories of people, particular types of movements grants; as well as those whose ecifically defined under
	What countries are included in t	he MENA region?
	 Algeria Bahrain Bohrain Morocco Egypt Occupied Palestinian Iraq Iraq Jordan Oman Kuwait Qatar Lebanon 	 Saudi Arabia Sudan Syrian Arab Republic Tunisia United Arab Emirates Yemen

Who is a migrant?

Figure 2 Definitions used in this project, adopted from the International Organization for Migration. References: International Organization for Migration. IOM definition of 'Migrant' Switzerland: International Organization of Migration (available from: https://www.iom.int/about-migration, accessed 4 April 2023). International Organization for Migration. IOM Middle East and North Africa regional strategy 2017–2020. Cairo 2017.

study eligibility criteria), interventions in the study (if necessary), list of barriers, facilitators or determinants of usage/under-usage, outcome measures and results (eg, frequency, percentages, 95% CIs, etc) where appropriate, and any adjustment conducted for confounding of the outcomes. Any missing statistical parameters of importance and variability measures (eg, 95% CIs) will be estimated, if data permit. All calculated or derived data will be denoted as 'calculated' and will be incorporated in the extraction sheets.

Risk of bias

Two independent authors will appraise the risk of bias for each included paper. For peer-reviewed literature, we will use the appropriate Joanna Briggs Institute tool for each study design and for grey literature records, we will use the Authority, Accuracy, Coverage, Objectivity, Date and Significance (AACODS) checklist.^{38 39} We will assess the quality of the policies using the most appropriate AGREE tool—AGREE II or AGREE HS.⁴⁰ The quality appraisals will be cross-checked and any disagreements will be resolved by a consensus-based discussion, with the involvement of a third reviewer if necessary. The individual item-specific quality assessment ratings for each study will be tabulated. Records will not be excluded based on quality assessment, but the appraisal will contribute to the synthesis and the discussion.

Data synthesis and analysis Disease indicators (question 1)

If the studies are sufficiently similar, we will combine the data using a proportional meta-analysis via a random effects model due to the anticipated heterogeneity that may result from the differences in methodology and study settings.⁴¹ There will be a separate pooled estimate for each disease indicator/outcome, and by type of migrant as appropriate. If there are sufficient data, there will be a separate pooled estimate of studies with adjustment and studies without adjustment. If we do not have sufficient data, adjusted and unadjusted studies will be pooled together for each disease indicator/outcome.

We will assess heterogeneity among studies by inspecting the forest plots and using the χ^2 test for heterogeneity with a 10% level of statistical significance and using the I² statistic where we interpret a value of 50% as representing moderate heterogeneity. We will assess the possibility of publication bias by evaluating funnel plot asymmetry and will also be conducted using an adjusted Egger's regression asymmetry test as a formal statistical test for publication bias for outcomes with 10 or more studies. We will perform a leave-one-study-out sensitivity analysis to determine the stability of the results. This analysis will evaluate the influence of individual studies by estimating the pooled analyses in the absence of each study. If there are sufficient data, we will investigate potential sources of heterogeneity, using metaregression, and incorporating the following covariates in each model: country of study, study period, type of migrant (labour, asylum seeker, refugee, undocumented, etc); setting/ housing (camps, community, detention, etc); comorbidities; country of birth/origin; age and sex. To assure confidence in the results of the meta-analyses, if there are sufficient studies, we will include the following sensitivity analyses: only studies rated low risk of bias, only peerreviewed studies, only studies that had adjustment for confounding factors and only prospective studies.

When studies cannot be combined for meta-analysis due to significant clinical heterogeneity, such as differences in participant characteristics, outcome measurements, and so on, narrative syntheses will be conducted and results of individual studies will be displayed in tables, texts and figures as appropriate, to enable a succinct summary of evidence. We will stratify the results by outcome and type of migrant and investigate heterogeneity qualitatively by exploring differences in results by country of study, study period, setting/housing, country of birth/origin, and so on, as appropriate.

Policy and access indicators (questions 2 and 3)

For policies (question 2), we will conduct narrative syntheses, and results of individual studies will be displayed in tables, texts and figures as appropriate, to enable a succinct summary of evidence. For access (question 3), we will use thematic analysis to group the facilitators/determinants of usage and barriers/determinants of underusage reported across studies into themes and display the results in tables, texts and figures, as appropriate. We will also stratify these results by type of migrant, country of study, study period, setting/housing and country of birth/origin, as appropriate.

All statistical analyses will be conducted in R statistical software (V.4.2.2).

Strengths and limitations

A strength of our systematic reviews is the extensive grey literature search (including searching international organisations, ministries of health for each country, reviewing reference lists, reviewing included studies with experts, and allowing a snowballing approach to find further information). However, it may be more challenging to identify all relevant sources across all countries, and the data retrieved may not be comprehensive, of high quality, and more complicated to synthesise. To assist this process, we will document all the sources searched and data identified by source, assess the quality of the grey literature and perform sensitivity analyses for peer-reviewed versus grey literature results. Another limitation in the scope of the NCDs systematic review is that we are limiting the diseases area to diabetes only. This is to make the suite of reviews feasible; however, it is not representative of the literature on all NCDs. Once this suite of reviews

is completed, we will undertake a second review on NCDs in migrant populations in the MENA region, including hypertension, cardiovascular disease, obesity and chronic kidney disease.

Patient and public involvement

Members of the MENA Migrant Health Working Group, including clinicians and policy-makers from the Ministries of Health, IOM, WHO, Médecins du Monde and Maroc Solidarité Médico-Sociale MS2, have been involved in the design of this protocol.

Ethics and dissemination

There are no ethical or safety issues. The seven systematic reviews will identify and summarise the relevant evidence on the data on disease burden, health outcomes, policies and barriers and facilitators to access in migrant populations in the MENA region. The findings of the systematic reviews will be summarised along with the methodological quality of the studies. Strengths and limitations of the review will be discussed and gaps in the evidence will be highlighted. The findings of these seven reviews, and those of other similar reviews or reports (if identified), will be compared.

We aim to publish each of the individual systematic reviews in peer-reviewed journals as the findings have global relevance so a peer-reviewed journal will give us this reach. In addition, we will present these findings in oral and poster presentations in relevant conferences nationally in the MENA region and internationally. We also intend to report the findings to ministries of health in Morocco, Tunisia and Egypt where, as mentioned in the introduction, we will be conducting the qualitative studies to continue the development of the MHCP-t. In addition, we will report some of these findings on our website for this project: the MENA Migrant Health project (http:// www.menamigranthealth.org/). We will explore innovative ways to do public engagement work to disseminate the findings of this work to community organisations, migrant groups, NGOs and others through our growing networks in the MENA region. We envisage that they may use these findings for advocacy work and to lobby for improved service provision locally and country wide.

The data on disease burden, health outcomes, policies and facilitators and barriers to access related to migrant health in the MENA region have not been systematically reviewed, yet they have important implications for the health and well-being of migrants and the health of the local populations. These findings will be discussed with a view to better inform the understanding of data in the MENA region and the indicators we should use in the MHCP tool. The findings will also contribute more widely as a basis for future research on migrant health in the region.

Author affiliations

¹St George's University of London Institute for Infection and Immunity, London, UK ²Barcelona Institute for Global Health, Barcelona, Catalunya, Spain

³Université Mohammed VI des Sciences et de la Santé, Casablanca, Casablanca-Settat, Morocco

⁴University of Gezira, Wad Madani, Sudan

- ⁵Badr University in Cairo, Cairo, Egypt
- ⁶University of Sousse, Sousse, Tunisia

⁷London School of Hygiene & Tropical Medicine, London, UK

⁸Ecole Nationale de Santé Publique, Rabat, Morocco

- ⁹Ajman University, Ajman, UAE
- ¹⁰Ministère de la Santé, Rabat, Morocco
- ¹¹Higher Institute of Nursing Professions and Health Techniques, Ministry of Health and Social Protection, Rabat, Morocco
- ¹²International Organization for Migration, Berlin, Germany
- ¹³Queen Mary University of London, London, UK
- ¹⁴Karolinska Institute, Stockholm, Sweden

X Farah Seedat @SeedatFarah and Mahmoud Hilali @mahmoudhilali6

Acknowledgements We would like to thank Sabina Gillsund and Narcisa Hannerz for developing the search strategies and all the members of the Middle East and North Africa Migrant Health Working Group: Asad Adam (University of Gezira, Sudan), Adnene Ben Haj Aissa (Office National de la Famille et de la Population. Tunisia), Charles Agvemang (University of Amsterdam, Netherlands), Salma Altvib (Ministry of Health, Sudan), Ali Ardalan (WHO Regional Office for the Eastern Mediterranean), Hanen Ben Belgacem (IOM Tunisia), Imane Belkhammar (Maroc Solidarité Médico-Sociale MS2, Morocco), Thomas Calvot (Médecins du Monde, Tunisia), Nuria Casamitjana (University of Barcelona, Spain), Luciana Ceretti (IOM Morocco), Nelly Chavassieux (Maroc Solidarité Médico-Sociale MS2, Morocco), Hassan Chrifi (Ecole Nationale de Santé Publique, Morocco) Mohamed Douagi (Office National de la Famille et de la Population, Tunisia), Algdail Elnil (Sudan Organization Network for Peace & Development, Sudan), Gonzalo Faniul (Institut for Global Health Barcelona, Spain), Fouad M Fouad (American University of Beirut, Lebanon), Chiaki Ito (IOM MENA), Abdedayem Khelifi (Office National de la Famille et de la Population. Tunisia). Lora Makhlouf (Médecins du Monde. Morocco). Maissa Mokni (Médecins du Monde, Tunisia), Davide Olchini (Médecins du Monde MENA), Tarik Oufkir (Maroc Solidarité Médico-Sociale MS2, Morocco), Nasong Park (IOM Egypt), Giuseppe Raffa (Médecins du Monde, Tunisia), Wafa Saidi (Ministry of Health, Tunisia), Sandra Santafé (Institut for Global Health Barcelona, Spain), Alice Sironi (IOM Tunisia), Fatma Temimi (Office National de la Famille et de la Population, Tunisia), Zeineb Turki (Médecins du Monde, Tunisia).

Collaborators The Middle East and North Africa Migrant Health Working Group: Adel Abdelkhalek (Badr University of Cairo), Asad Adam (University of Gezira, Sudan), Adnene Ben Haj Aissa (Office National de la Famille et de la Population, Tunisia), Charles Agvemang (University of Amsterdam, Netherlands), Salma Altvib (Ministry of Health, Sudan), Ali Ardalan (WHO Regional Office for the Eastern Mediterranean), Hanen Ben Belgacem (IOM Tunisia), Imane Belkhammar (Maroc Solidarité Médico-Sociale MS2, Morocco), Thomas Calvot (Médecins du Monde, Tunisia), Nuria Casamitjana (University of Barcelona, Spain), Luciana Ceretti (IOM Morocco), Nelly Chavassieux (Maroc Solidarité Médico-Sociale MS2, Morocco), Hassan Chrifi (Ecole Nationale de Santé Publique, Morocco) Mohamed Douagi (Office National de la Famille et de la Population, Tunisia), Algdail Elnil (Sudan Organization Network for Peace & Development, Sudan), Gonzalo Fanjul (Institut for Global Health Barcelona, Spain), Fouad M Fouad (American University of Beirut, Lebanon), Ahmed Hamed (Badr University of Cairo), Chiaki Ito (IOM MENA), Abdedayem Khelifi (Ecole Nationale de Santé Publique, Morocco), Lora Makhlouf (Médecins du Monde, Morocco), Maissa Mokni (Médecins du Monde, Tunisia), Davide Olchini (Médecins du Monde MENA), Tarik Oufkir (Maroc Solidarité Médico-Sociale MS2, Morocco), Nasong Park (IOM Egypt), Giuseppe Raffa (Médecins du Monde, Tunisia), Wafa Saidi (Ministry of Health, Tunisia), Sandra Santafé (Institut for Global Health Barcelona, Spain), Alice Sironi (IOM Tunisia), Fatma Temimi (Office National de la Famille et de la Population, Tunisia), Zeineb Turki (Médecins du Monde, Tunisia).

Contributors AR-M, KW and SH conceptualised the idea for this project. FS planned the overall methodology for the reviews, coordinated the reviews and led the write up of this manuscript. MA, AC-G, LMP, OB, HE, EE, TM and AO adapted the overarching methodology for each disease area and will be the first and second reviewers for the systematic reviews. AD and SA contributed to the review on vaccination. SE, AA, AC, AHA, BA, IAB, KH, WC-E, MH, AI, MK, WM, AM, DZ, AR-M and SH supervised the reviews. All authors including experts in the MENA Migrant

Health Working Group contributed their technical expertise to the methodology. All authors were involved in the drafting and reviewing of the manuscript. During the preparation of this work, FS drafted the manuscript on Microsoft Word and then used Chat GPT 3.5/4.0 in order to proof-read and refine the language of some paragraphs of the draft. After using this tool, FS reviewed and edited the content as needed to ensure the manuscript reflected the intended message and takes full responsibility for the content of the publication.

Funding This work was supported by La Caixa, LCF/PR/SP21/52930003. AD is funded by the Medical Research Council (MRC/N013638/1). SH is funded by the National Institute for Health Research (NIHR300072), the Academy of Medical Sciences (SBF005\1111), the Medical Research Council (MRC/N013638/1), WHO, and Research England.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Farah Seedat http://orcid.org/0000-0002-3563-7875 Oumnia Bouaddi http://orcid.org/0000-0001-9114-6889 Hassan Edries http://orcid.org/0000-0002-3114-6358 Kenza Hassouni http://orcid.org/0000-0002-7605-895X Mohamed Khalis http://orcid.org/0000-0003-4639-049X Ana Requena-Mendez http://orcid.org/0000-0002-4422-241X

REFERENCES

- Requena-Méndez A, Wickramage K, Ito C, *et al.* Understanding health inequities among transiting migrants within the middle East and North African (MENA) region through strengthening data systems. *Travel Med Infect Dis* 2021;42:102094.
- 2 United Nations High Commissioner for Refugees (UNHCR). Global report, 2022. Available: https://reporting.unhcr.org/operational/ regions/middle-east-and-north-africa#:~:text=By%20the%20end% 20of%202022,uncertain%20funding%20situation%20in%202022 [Accessed 1 Jun 2023].
- 3 United Nations High Commissioner For Refugees (UNHCR). Sudan situation. UNHCR; 2023. Available: https://reliefweb.int/report/sudan/ sudan-situation-unhcr-external-update-41-19-25-december-2023 [Accessed 27 Dec 2023].
- 4 Office of the United Nations High Commissioner for Human Rights. Israel working to expel civilian population of Gaza. UN expert warns: OHCHR; 2023. Available: https://www.ohchr.org/en/press-releases/ 2023/12/israel-working-expel-civilian-population-gaza-un-expertwarns [Accessed 27 Dec 2023].
- 5 Human Rights Watch. No escape from hell. 2019.
- 6 Knoll A, Teevan C. Protecting migrants and refugees in North Africa: challenges and opportunities for reform. *ECPDM* 2020;21:2020.
- 7 Garbout W. The failure of an effective humanitarian response to protect sub-Saharan African refugees and asylum Seekers. Lebanese American University, 2021
- 8 Ministère Délégué Auprès du Ministre des Affaires Étrangères et de la Coopération. Politique Nationale D'Immigration et D'Asile Rapport 2018 Morocco, 2018. Available: http://

6

Open access

marocainsdumonde.gov.ma/ewhatisi/2019/01/Politique-Nationaledimmigration-et-dAsile-_-Rapport-2018.pdf [Accessed 1 Jun 2023].

- 9 Ministère Délégué Auprès Du Ministre des Affaires Étrangères et de la Coopération. National Immigration and Asylum Strategy Morocco. Available: https://marocainsdumonde.gov.ma/en/nationalimmigration-and-asylum-strategy [Accessed 1 Jun 2023].
- 10 Msakni F. Tunisian Forum for Economic and Social Rights; From sub-Saharan African States to Tunisia. A quantitative study on the situation of migrants in Tunisia: general aspects, pathways and aspirations, 2020. Available: https://ftdes.net/en/from-sub-saharanafrican-states-to-tunisia-a-quantitative-study-on-the-situation-ofmigrants-in-tunisia-general-aspects-pathways-and-aspirations [Accessed 19 Apr 2023].
- 11 International Organization for Migration. Migrant inclusion in COVID-19 vaccination deployment, 2022. Available: https://www. iom.int/sites/g/files/tmzbdl486/files/documents/iom-vaccineinclusion-mapping-global-march-2022-external-final.pdf
- 12 Kuehne A, van Boetzelaer E, Alfani P, *et al.* Health of migrants, refugees and asylum seekers in detention in Tripoli, Libya 2018-2019: retrospective analysis of routine medical programme data. *PLoS One* 2021;16:e0252460.
- 13 World Health Organization. World report on the health of refugees and migrants. In: World Health Organization. Geneva, 2022.
- 14 World Health Organization. Ensuring the integration of refugees and migrants. In: *Immunization policies, planning and service delivery globally*. 2022.
- 15 World Health Organization. Geneva: WHO; WHO immunisation agenda 2030: a global strategy to leave no one behind, 2020. Available: https://www.who.int/teams/immunization-vaccines-andbiologicals/strategies/ia2030 [Accessed 2 Jun 2023].
- 16 Shawky S, Soliman C, Kassak KM, *et al.* HIV surveillance and epidemic profile in the Middle East and North Africa. *J Acquir Immune Defic Syndr* 2009;51 Suppl 3:S83–95.
- 17 UNAIDS. Middle East and North Africa regional report on AIDS. UNAIDS: joint United Nations programme on HIV/AIDS: UNAIDS. 2011. Available: https://www.unaids.org/sites/default/files/media_ asset/JC2257_UNAIDS-MENA-report-2011_en_1.pdf [Accessed 16 Jun 2023].
- 18 Saaed FMA, Ongerth JE. Prevalence of hepatitis B and hepatitis C in migrants from sub-Saharan Africa before onward dispersal toward Europe. J Immigr Minor Health 2023;25:882–8.
- 19 Al-Awadhi M, Ahmad S, Iqbal J. Current status and the epidemiology of malaria in the Middle East region and beyond. *Microorganisms* 2021;9:338.
- 20 Kronfol NM, Mansour Z. Tuberculosis and migration: a review. East Mediterr Health J 2013;19:739–48.
- 21 Alam W, Mobayed T, Younis N, *et al*. Neglected tropical diseases in Lebanon. *Acta Parasitol* 2022;67:809–19.
- 22 Naja F, Shatila H, El Koussa M, et al. Burden of non-communicable diseases among Syrian refugees: a scoping review. BMC Public Health 2019;19:637.
- 23 Al-Hatimy F, Farooq A, Al Abiad M, et al. A retrospective study of non-communicable diseases amongst blue-collar migrant workers in Qatar. Int J Environ Res Public Health 2022;19:2266.
- 24 Morina N, Akhtar A, Barth J, et al. Psychiatric disorders in refugees and internally displaced persons after forced displacement: a systematic review. Front Psychiatry 2018;9:433.

- 25 Kronfol Z, Saleh M, Al-Ghafry M. Mental health issues among migrant workers in Gulf Cooperation Council countries: literature review and case illustrations. *Asian J Psychiatr* 2014;10:109–13.
- 26 McCall SJ, El Khoury TC, Ghattas H, *et al.* Maternal and infant outcomes of Syrian and Palestinian refugees, Lebanese and migrant women giving birth in a tertiary public hospital in Lebanon: a secondary analysis of an obstetric database. *BMJ Open* 2023;13:e064859.
- 27 McNatt ZZ. Addressing noncommunicable diseases among urban refugees in the Middle East and North Africa - a scoping review. *Confl Health* 2020;14:9.
- 28 Ismail ITA, EI-Tayeb EM, Omer MDFA, et al. Assessment of routine immunization coverage in nyala locality, reasons behind incomplete immunization in South Darfur state, Sudan. Asian J Med Sci 2014;6:1–8.
- 29 Elhadi FE, Ibrahim IA. Measles vaccination among children (12 to 23 months) in ldps settlements of Khartoum state, Sudan. Int J CHILD HEALTH Nutr 2015;4:135–40.
- 30 Abubakar I, Aldridge RW, Devakumar D, et al. The UCL-lancet Commission on migration and health: the health of a world on the move. *The Lancet* 2018;392:2606–54.
- 31 Migration Health Research Portal. International Organization for Migration; Fostering health and protection to vulnerable migrants transiting through Morocco, Tunisia, Egypt, Libya and Yemen, 2018. Available: https://migrationhealthresearch.iom.int/proposal/fosteringhealth-and-protection-vulnerable-migrants-transiting-throughmorocco-tunisia [Accessed 12 Jun 2023].
- 32 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:71.
- 33 McMaster University. Search filters for MEDLINE in ovid syntax and the PubMed translation Canada, 2019. Available: https://hiruweb. mcmaster.ca/hkr/hedges/medline/ [Accessed 27 Dec 2023].
- 34 The InterTASC Information Specialists' Sub-Group. Search filters resource: ISSG. 2023. Available: https://sites.google.com/a/york. ac.uk/issg-search-filters-resource/home/recently-added-filters#h. acmijzu6dh5s [Accessed 27 Dec 2023].
- 35 National Institute for Health and Care Excellence. HIV infection and AIDS: search strategy England. NICE; 2021. Available: https://cks. nice.org.uk/topics/hiv-infection-aids/how-this-topic-was-developed/ search-strategy/ [Accessed 27 Dec 2023].
- 36 National Institute for Health and Care Excellence. Malaria: search strategy England. NICE; 2023. Available: https://cks.nice.org.uk/ topics/malaria/how-this-topic-was-developed/search-strategy/ [Accessed 27 Dec 2023].
- 37 National institute for health and care excellence. Tuberculosis: search strategy England. NICE; 2023. Available: https://cks.nice.org.uk/ topics/tuberculosis/how-this-topic-was-developed/search-strategy/ [Accessed 27 Dec 2023].
- 38 Vardell E, Malloy M. Joanna Briggs Institute: an evidence-based practice database. *Med Ref Serv Q* 2013;32:434–42.
- 39 Tyndall J. AACODS checklist. Flinders University; 2010.
- 40 Brouwers MC, Spithoff K, Lavis J, et al. What to do with all the AGREES? the AGREE portfolio of tools to support the guideline enterprise. J Clin Epidemiol 2020;125:191–7.
- 41 Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol 2021;21:189.

Defining indicators for disease burden, health outcomes, policies, and barriers and facilitators to health services for migrant populations in the Middle East and North African region: a protocol for a suite of systematic reviews

Farah Seedat, Stella Evangelidou, Moudrick Abdellatifi, Oumnia Bouaddi, Alba Cuxart-Graell, Hassan Edries, Eman Elafef, Taha Maatoug, Anissa Ouahchi, Liv Mathilde Pampiri, Anna Deal, Sara Arias, Adel Abdelkhalek, Ahmed Hamed Arisha, Bouchra Assarag, Ibrahim Bani, Aasmaa Chaoui, Wafa Chemao-Elfihri, Kenza Hassouni, Mahmoud Hilali, , Mohamed Khalis, Wejdene Mansour, Ali Mtiraoui, Kolitha Wickramage, Dominik Zenner, Ana Requena-Mendez*, and Sally Hargreaves*, on behalf of the MENA Migrant Health Working Group

*Joint senior authors, who have contributed equally

Table of Contents

Draft	search strategies	2
1.	HIV and Hepatitis B and C	2
2.	Malaria and NTDs	4
3.	Tuberculosis	7
4.	Vaccine preventable diseases	9
5.	Maternal and neonatal health	12
6.	Diabetes	15
7.	Mental health	17
PRISN	1A study flow diagram	. 20

Draft search strategies for the systematic review on health indicators and policy review on policies for each disease area separately

1. HIV and Hepatitis B and C

	base(s): Ovid MEDLINE(R) ALL 1946 to February 01, 2023	
Sear	ch Strategy:	
#	Searches	Results
1	exp Human Migration/	27701
2	exp "Emigrants and Immigrants"/	15313
3	"Transients and Migrants"/	13959
4	Refugees/	12840
5	Refugee Camps/	284
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	573213
7	or/1-6	586984
8	exp Middle East/	161654
9	exp Africa, Northern/	40959
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	317472
11	or/8-10	436405
12	exp Blood-Borne Infections/ or Hepatitis, Viral, Human/	428828

13	(acquired immunodeficien* syndrome* or AIDS or bloodborne disease* or blood borne disease* or bloodborne infection* or blood borne infection* or Hepatitis B or HBV or Hepatitis C or HCV or HIV or human immunodeficien* virus* or viral hepatitis or viral liver disease*).ti,ab,kf.	616455
14	or/12-13	666140
15	7 and 11 and 14	721
16	(animals not humans).sh.	5054628
17	15 not 16	719
18	limit 17 to yr="2000 -Current"	535

2. Malaria and NTDs

	Database(s): Ovid MEDLINE(R) ALL 1946 to February 24, 2023 Search Strategy:	
#	Searches	Results
1	exp Human Migration/	27722
2	exp "Emigrants and Immigrants"/	15372
3	"Transients and Migrants"/	14022
4	Refugees/	12903
5	Refugee Camps/	288
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	573858
7	or/1-6	587633
8	exp Middle East/	159113
9	exp Africa, Northern/	41057
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	318043
11	or/8-10	434382
12	Neglected Diseases/	2424
13	exp Malaria/ or exp Plasmodium/	90811
14	Buruli Ulcer/ or Mycobacterium ulcerans/	1098

15	exp Dengue/ or exp Arbovirus Infections/ or exp Flavivirus Infections/	52097
16	Chikungunya Fever/	2723
17	Dracunculiasis/	907
18	exp Echinococcosis/	20591
19	exp Trematode Infections/	37974
20	Trypanosomiasis, African/ or Trypanosomiasis/ or Euglenozoa Infections/	10112
21	exp Leishmaniasis/	25341
22	exp Leprosy/ or Mycobacterium leprae/	24706
23	Elephantiasis, Filarial/ or Wuchereria bancrofti/	4066
24	Mycetoma/ or exp Dermatomycoses/	29882
25	exp Onchocerciasis/ or exp Filariasis/ or Onchocerca volvulus/	16005
26	Rabies/ or exp Rhabdoviridae Infections/	13177
27	Scabies/ or exp Ectoparasitic Infestations/	22522
28	exp Schistosomiasis/	24882
29	exp Helminthiasis/	134192
30	Snake Bites/	5405
31	exp Taeniasis/ or exp Cestode Infections/ or exp Cysticercosis/ or Neurocysticercosis/	33945
32	Trachoma/ or exp Conjunctivitis, Bacterial/	6181
33	Treponemal Infections/ or Yaws/ or Treponema pallidum/	5990
34	(neglected adj3 disease*).ti,ab,kf.	8699
35	((arbovirus or echinococcus or euglenozoa or flavivirus or nematomorpha or rhabdoviridae or schistoma or trematode or treponemal) adj3 infection*).ti,ab,kf.	3845
36	(actinomycetoma or african sleeping sickness* or african trypanosomias?s or bacterial conjunctivitis or bancroftian elephantias?s or bancroftian filarias?s or bejel* or bilharsia* or bilharzias?s or black fever or borderline tuberculoid* or breakbone fever or break bone fever or buruli ulcer or chikungunya or coenuri* or coenuros?s or coenurus cerebralis or cysticercos?s or cysticercus cellulosae or deep mycos?s or dengue* or dermatomycos?s or	350022

	dracuncul* or echinococcos?s or ectoparasitic infestation* or ectoparasitos?s or egyptian	
	ophthalmia or eumycetoma or filarial elephantias?s or filariose or filiariasis or frambesia	
	or guinea worm disease* or hansen* disease* or helminthias?s or hydatid cysts or	
	hydatidos?s or hydrophobia or kalazar or kala azar or katayama fever or leishmani* or	
	leprae or leepre or leprosies or leprosy or lymphatic filarias?s or lyssa or lyssas or madura	
	foot or maduromycosis or malare or malaria or malayi elephantias?s or malayi filarias?s	
	or myceetome or mycetoma or mycobacterium ulcerans or nagana or neurocysticercos?s	
	or neuroschistosomias?s or onchocercias?s or onchocerca volvulus or onchocercose or	
	oriental sore or plasmodium falciparum or paludisme or rabies or raby or river blindness	
	or sarcoptic mange or scabies or schistosomias?s or schistosomal myel* or snakebite* or	
	snake bite* or snake envenoming or taenia* or taenias?s or teeniase or trachoma* or	
	treponema pallidum or treponematos?s or trypanosomiase or trypanosoma or	
	trypanosomiasis or ulceere or ulcer disease* or wuchereria bancrofti or yaw or yaws or	
	zazzabin cizon sauro).ti,ab,kf.	
37	or/12-36	543044
37	0712-50	545044
38	7 and 11 and 37	1064
39	(animals not humans).sh.	5062487
40	38 not 39	967
41	limit 40 to yr="2000 -Current"	692

3. Tuberculosis

	Database(s): Ovid MEDLINE(R) ALL 1946 to February 21, 2023 Search Strategy:		
#	Searches	Results	
1	exp Human Migration/	27721	
2	exp "Emigrants and Immigrants"/	15365	
3	"Transients and Migrants"/	14005	
4	Refugees/	12901	
5	Refugee Camps/	288	
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	573334	
7	or/1-6	587109	
8	exp Middle East/	159051	
9	exp Africa, Northern/	41052	
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	317712	
11	or/8-10	433998	
12	exp Tuberculosis/	204795	
13	(koch* disease or koch's disease or tuberculo?s*).ti,ab,kf.	248090	
14	(TB adj3 (active or case* or disease* or infection* or latent)).ti,ab,kf.	18905	

15	or/12-14	278936
16	7 and 11 and 15	472
17	(animals not humans).sh.	5061699
18	16 not 17	471
19	limit 18 to yr="2000 -Current"	371

4. Vaccine preventable diseases

Database(s): Ovid MEDLINE(R) ALL 1946 to February 13, 2023 Search Strategy:		
#	Searches	Results
1	exp Human Migration/	27716
2	exp "Emigrants and Immigrants"/	15329
3	"Transients and Migrants"/	13990
4	Refugees/	12879
5	Refugee Camps/	286
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	572839
7	or/1-6	586614
8	exp Middle East/	161966
9	exp Africa, Northern/	41016
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	317516
11	or/8-10	436655
12	exp Vaccines/	272039
13	exp Immunization/	205597
14	exp Immunization Programs/	15956

9

15	(immunostimulation* or immunisation* or immunization* or vaccin* or variolation*).ti,ab,kf.	461660
16	(immunologic* adj2 (sensiti?ation* or stimulation*)).ti,ab,kf.	603
17	Vaccine-Preventable Diseases/	225
18	Cholera/	9238
19	COVID-19/	213155
20	exp Dengue/	15622
21	Diphtheria/	6934
22	exp Hepatitis B/	64040
23	Haemophilus influenzae type b/ or Haemophilus Infections/	8717
24	exp Papillomaviridae/	37470
25	Influenza, Human/	56964
26	Measles/	14748
27	exp Meningococcal Infections/	11761
28	Mumps/	4847
29	Whooping Cough/	9095
30	exp Pneumococcal Infections/	22359
31	exp Poliomyelitis/	20598
32	Rabies/	10830
33	Rubella/	8278
34	Rotavirus Infections/	8644
35	Tetanus/	9782
36	exp Tuberculosis/	204709
37	exp Varicella Zoster Virus Infection/	19758
38	(vaccine preventable adj3 (disease* or illness* or infection*)).ti,ab,kf.	4284

39	(2019 ncov or 2019ncov or breakbone fever or break-bone fever or chickenpox* or chicken pox* or cholera* or cholerae or coqueluche or coronavirus 2 or corona virus disease 2019 or cov2 or cov 2 or covid-19 or covid19 or dengue* or diphtheri* or diphteri* or epidemic parotiti* or german measles or grippe or h1n1 or hav or haemophilus or hbv or hepa or hepatit* or herpesvirus 3 or hepb or hib or hpv or human flu or human papilloma* virus* or hydrophobia or influenza* or koch* disease or lyssa or lyssas or measles or meningit* or meningoco* or mumps or ncov or neisseria meningitidis or neonatal calf diarrhea virus* or new corona virus* or new coronavirus* or novel corona virus* or novel coronavirus* or oreillons or pachymeningiti* or papillomavir* or pertuss* or pfeiffer* bacillus or pneumococcal or pneumoniae or polio* or rabies or rotavirus* or rougeol* or rubella* or rubeol* or sars-cov-2 or sars2 or tdap or tdp or tetani or tetanus* or three day measle* or tuberculos* or varicella or whooping cough*).ti,ab,kf.	1340987
40	or/12-39	1744210
41	7 and 11 and 40	1725
42	(animals not humans).sh.	5059283
43	41 not 42	1682
44	limit 43 to yr="2000 -Current"	1397

5. Maternal and neonatal health

	Database(s): Ovid MEDLINE(R) ALL 1946 to March 23, 2023 Search Strategy:	
#	Searches	Results
1	exp Human Migration/	27742
2	exp "Emigrants and Immigrants"/	15413
3	"Transients and Migrants"/	14073
4	Refugees/	12961
5	Refugee Camps/	287
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	576748
7	or/1-6	590527
8	exp Middle East/	159720
9	exp Africa, Northern/	41145
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	319881
11	or/8-10	436540
12	Maternal Health/ or Maternal Welfare/	8804
13	exp Maternal Health Services/ or Maternal-Child Health Centers/	58953
14	Maternal Mortality/ or Maternal Death/	11807

15	Hypertension, Pregnancy-Induced/ or Pre-Eclampsia/	38475
16	Diabetes, Gestational/	14923
17	Depression, Postpartum/	7293
18	Postpartum Hemorrhage/	8327
19	Anemia, Iron-Deficiency/	11555
20	Pregnancy Complications, Infectious/ or Puerperal Infection/	44906
21	Pregnancy/	978234
22	Gravidity/	1308
23	Pregnancy, High-Risk/ or Pregnancy, Unplanned/ or Pregnancy, Unwanted/	9870
24	Pregnant Women/	13892
25	Pregnancy Trimester, Third/	15768
26	Peripartum Period/	1713
27	exp Delivery, Obstetric/ or Labor, Obstetric/ or Labor Onset/ or exp Labor Presentation/ or "Trial of Labor"/ or Uterine Contraction/	121577
28	Birth Setting/ or Home Childbirth/ or Natural Childbirth/ or Term Birth/	8431
29	Pregnancy Outcome/ or Abortion, Spontaneous/ or Stillbirth/ or Abortion, Incomplete/ or Embryo Loss/ or Abortion, Threatened/	84632
30	Uterine Cervical Incompetence/	1571
31	Obstetric Labor Complications/ or Dystocia/ or Premature Birth/	41246
32	Infant Health/	1251
33	exp Infant Mortality/	31664
34	exp Infant, Low Birth Weight/	38613
35	exp Infant, Premature/	64190
36	(birth* or child bearing or childbearing or childbirth* or expect* mother* or gestation* or gravidit* or multigravidit* or nulligravidit* or obstetric deliver* or pregnan* or primigravidit*).ti,ab,kf.	968064

27	((antenatal* or ante natal* or maternal or perinatal* or peri natal* or peripartum or peri	42045
37	partum or postnatal or post natal or postpartum or post partum or puerperium) adj3 (care or clinic* or healthcare or service*)).ti,ab,kf.	42845
	(abortion* or breech presentation* or dystocia* or embryo death or embryo loss or embryo resorption or fetal presentation* or incompetent cervi* or labor complication* or	
38	labor onset* or labor presentation* or labor trial or obstetric labor or prematurity or "trial	111733
	of labor" or uterine contraction* or uterine cervi* incompetence).ti,ab,kf.	
39	((prematur* or preterm or pre-term) adj3 (baby or babies or child* or deliver* or infant* or neonat* or newborn*)).ti,ab,kf.	95191
40	((low or small) adj3 (birthweight* or birth weight* or gestational age)).ti,ab,kf.	51845
41	(an?emia* or fetal macrosomia* or gestational diabetes or gestational hypertension or postpartum sepsis or pre-eclampsia or preeclampsia or puerperal infection* or	240331
41	stillbirth*).ti,ab,kf.	240331
42	((postnatal or post natal or postpartum or post partum) adj2 (depress* or dysphoria* or h?emorrhage*)).ti,ab,kf.	18564
43	((baby or babies or infant* or maternal* or neonat* or newborn* or peri natal* or perinatal*) adj3 (death* or health* or mortalit*)).ti,ab,kf.	135076
44	or/12-43	1658543
45	7 and 11 and 44	1881
46	(animals not humans).sh.	5071308
47	45 not 46	1843
48	limit 47 to yr="2000 -Current"	1308
	·	·1

6. Diabetes

	Database(s): Ovid MEDLINE(R) ALL 1946 to May 25, 2023 Search Strategy:	
#	Searches	Results
1	exp Human Migration/	27778
2	exp "Emigrants and Immigrants"/	15514
3	"Transients and Migrants"/	14172
4	Refugees/	13100
5	Refugee Camps/	289
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	583255
7	or/1-6	597041
8	exp Middle East/	160899
9	exp Africa, Northern/	41353
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	323995
11	or/8-10	441338

12	exp Diabetes Mellitus/	504402
13	exp Insulin Resistance/	98730
14	(diabet* or insulin* or metabolic syndrome* or cardiometabolic syndrome* or dysmetabolic syndrome* or reaven syndrome*).ti,ab,kf.	1034882
15	or/12-14	1092851
16	7 and 11 and 15	599
17	(animals not humans).sh.	5090355
18	16 not 17	590
19	limit 18 to yr="2000 -Current"	541


7. Mental health

	Database(s): Ovid MEDLINE(R) ALL 1946 to June 08, 2023 Search Strategy:		
#	Searches	Results	
1	exp Human Migration/	27795	
2	exp "Emigrants and Immigrants"/	15560	
3	"Transients and Migrants"/	14191	
4	Refugees/	13137	
5	Refugee Camps/	291	
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	584365	
7	or/1-6	598153	
8	exp Middle East/	161066	
9	exp Africa, Northern/	41399	
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	324777	
11	or/8-10	442219	

12	Mental Health/ or exp Mental Disorders/ or Depression/ or Anxiety/ or Resilience, Psychological/	1608207
13	(mental adj2 (disorder* or distress or health or ill-being or illbeing or illness* or ill health or illhealth or instabilit* or symptom* or wellbeing or well-being or wellness)).ti,ab,kf.	299115
14	((psychiatric or psychologic*) adj3 (disorder* or distress or ill-being or illbeing or ill health or illhealth or illness* or problem* or resilienc* or symptom*)).ti,ab,kf.	141346
15	((drug* or heroin or inhalant* or marijuana or morphine or opium or substance*) adj3 (abuse* or addict* or dependenc* or habituation*)).ti,ab,kf.	91981
16	(alcoholic intoxication* or alcoholic psychos* or alcoholism or alcohol withdrawal delirium or binge drinking or opiate overdose or substance-induced psychos*).ti,ab,kf.	39664
17	((alcoholic korsakoff or asperger* or battered child or capgras or creutzfeldt-jakob or female athlete triad or jet lag or kleine-levin or kluver-bucy or munchausen or neonatal abstinence or night eating or restless legs or rumination or substance withdrawal or tourette*) adj3 syndrome*).ti,ab,kf.	16164
18	((adjustment or affective or alcohol-related or amphetamine-related or attention deficit or auditory perceptual or autistic or autism or bipolar or body dysmorphic or child behavio?r* or (pervasive adj2 development*) or cocaine-related or cognition or combat or communication or conduct or consciousness or excessive somnolence or disruptive behavio?r* or dissociative or "drug use" or eating or elimination or factitious or feeding or gender or hoarding or hyperactivity or impulse control or mood or motor or motor skill* or narcotic-related or neurocognitive or neurodevelopmental or neurotic or obsessive- compulsive or opioid-related or panic or paranoid or paraphilic or personality or phobic or psychotic or sexual or sleep* or sleep wake or somatoform or stress* or substance- related or tic or "tobacco use" or trauma) adj3 disorder*).ti,ab,kf.	346123
19	(agoraphobia or alzheimer disease or amnesia or anorexia nervosa or anxiety or bulimia nervosa or cataplexy or chemotherapy-related cognitive impairment or cognitive dysfunction* or delirium or delusional parasitosis or dementia* or depression* or developmental disabilit* or diabulimia or "diffuse neurofibrillary tangles with calcification" or diurnal enuresis or dyscalculia or dyslexia or dyspareunia or dyssomnia* or emergence delirium or encopresis or enuresis or erectile dysfunction or exhibitionism or firesetting behavior* or food addict* or frontotemporal lobar degeneration or	1001530

	gambling or gender dysphoria* or globus sensation or historical trauma* or huntington	
	disease or hypochondriasis or hysteria* or idiopathic hypersomnia or intellectual	
	disabilit* or kinesiophobia* or learning disabilit* or lewy body disease or masochism or	
	morgellons disease or mutism or narcolepsy or neurasthenia or neurocirculatory asthenia	
	or neurosis or neuroses or night terror* or nocturnal enuresis or nocturnal paroxysmal	
	dystonia or orthorexia nervosa or parasomnia* or pedophilia or phencyclidine abuse* or	
	pica or "pick disease of the brain" or postoperative cognitive complication* or premature	
	ejaculation or primary progressive aphasia or primary progressive nonfluent aphasia* or	
	psychiatric fetishism or psychological sexual dysfunction* or psychological trauma* or	
	pure alexia or "relative energy deficiency in sport" or rem sleep parasomnia* or sadism or	
	schizophrenia or sexual trauma* or sleep bruxism or sleep deprivation* or sleep paralysis	
	or sluggish cognitive tempo or social phobia* or somnambulism or transvestism or	
	trichotillomania or vaginismus or voyeurism or wernicke encephalopathy).ti,ab,kf.	
20	or/12-19	2205440
21	7 and 11 and 20	2636
22	(animals not humans).sh.	5094204
23	21 not 22	2629
24	limit 23 to yr="2000 -Current"	2326

PRISMA study flow diagram



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: <u>http://www.prisma-statement.org/</u>

Defining indicators for disease burden, health outcomes, policies, and barriers and facilitators to health services for migrant populations in the Middle East and North African region: a protocol for a suite of systematic reviews

Farah Seedat, Stella Evangelidou, Moudrick Abdellatifi, Oumnia Bouaddi, Alba Cuxart-Graell, Hassan Edries, Eman Elafef, Taha Maatoug, Anissa Ouahchi, Liv Mathilde Pampiri, Anna Deal, Sara Arias, Adel Abdelkhalek, Ahmed Hamed Arisha, Bouchra Assarag, Ibrahim Bani, Aasmaa Chaoui, Wafa Chemao-Elfihri, Kenza Hassouni, Mahmoud Hilali, , Mohamed Khalis, Wejdene Mansour, Ali Mtiraoui, Kolitha Wickramage, Dominik Zenner, Ana Requena-Mendez*, and Sally Hargreaves*, on behalf of the MENA Migrant Health Working Group

*Joint senior authors, who have contributed equally

Table of Contents

Draft	Draft search strategies				
1.	HIV and Hepatitis B and C	2			
2.	Malaria and NTDs	4			
3.	Tuberculosis	7			
4.	Vaccine preventable diseases	9			
5.	Maternal and neonatal health	12			
6.	Diabetes	15			
7.	Mental health	17			
PRISMA study flow diagram					

Draft search strategies for the systematic review on health indicators and policy review on policies for each disease area separately

1. HIV and Hepatitis B and C

	Database(s): Ovid MEDLINE(R) ALL 1946 to February 01, 2023		
Search Strategy:			
#	Searches	Results	
1	exp Human Migration/	27701	
2	exp "Emigrants and Immigrants"/	15313	
3	"Transients and Migrants"/	13959	
4	Refugees/	12840	
5	Refugee Camps/	284	
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	573213	
7	or/1-6	586984	
8	exp Middle East/	161654	
9	exp Africa, Northern/	40959	
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	317472	
11	or/8-10	436405	
12	exp Blood-Borne Infections/ or Hepatitis, Viral, Human/	428828	

13	(acquired immunodeficien* syndrome* or AIDS or bloodborne disease* or blood borne disease* or bloodborne infection* or blood borne infection* or Hepatitis B or HBV or Hepatitis C or HCV or HIV or human immunodeficien* virus* or viral hepatitis or viral liver disease*).ti,ab,kf.	616455
14	or/12-13	666140
15	7 and 11 and 14	721
16	(animals not humans).sh.	5054628
17	15 not 16	719
18	limit 17 to yr="2000 -Current"	535

2. Malaria and NTDs

	Database(s): Ovid MEDLINE(R) ALL 1946 to February 24, 2023 Search Strategy:		
#	Searches	Results	
1	exp Human Migration/	27722	
2	exp "Emigrants and Immigrants"/	15372	
3	"Transients and Migrants"/	14022	
4	Refugees/	12903	
5	Refugee Camps/	288	
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	573858	
7	or/1-6	587633	
8	exp Middle East/	159113	
9	exp Africa, Northern/	41057	
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	318043	
11	or/8-10	434382	
12	Neglected Diseases/	2424	
13	exp Malaria/ or exp Plasmodium/	90811	
14	Buruli Ulcer/ or Mycobacterium ulcerans/	1098	

15	exp Dengue/ or exp Arbovirus Infections/ or exp Flavivirus Infections/	52097
16	Chikungunya Fever/	2723
17	Dracunculiasis/	907
18	exp Echinococcosis/	20591
19	exp Trematode Infections/	37974
20	Trypanosomiasis, African/ or Trypanosomiasis/ or Euglenozoa Infections/	10112
21	exp Leishmaniasis/	25341
22	exp Leprosy/ or Mycobacterium leprae/	24706
23	Elephantiasis, Filarial/ or Wuchereria bancrofti/	4066
24	Mycetoma/ or exp Dermatomycoses/	29882
25	exp Onchocerciasis/ or exp Filariasis/ or Onchocerca volvulus/	16005
26	Rabies/ or exp Rhabdoviridae Infections/	13177
27	Scabies/ or exp Ectoparasitic Infestations/	22522
28	exp Schistosomiasis/	24882
29	exp Helminthiasis/	134192
30	Snake Bites/	5405
31	exp Taeniasis/ or exp Cestode Infections/ or exp Cysticercosis/ or Neurocysticercosis/	33945
32	Trachoma/ or exp Conjunctivitis, Bacterial/	6181
33	Treponemal Infections/ or Yaws/ or Treponema pallidum/	5990
34	(neglected adj3 disease*).ti,ab,kf.	8699
35	((arbovirus or echinococcus or euglenozoa or flavivirus or nematomorpha or rhabdoviridae or schistoma or trematode or treponemal) adj3 infection*).ti,ab,kf.	3845
36	(actinomycetoma or african sleeping sickness* or african trypanosomias?s or bacterial conjunctivitis or bancroftian elephantias?s or bancroftian filarias?s or bejel* or bilharsia* or bilharzias?s or black fever or borderline tuberculoid* or breakbone fever or break bone fever or buruli ulcer or chikungunya or coenuri* or coenuros?s or coenurus cerebralis or cysticercos?s or cysticercus cellulosae or deep mycos?s or dengue* or dermatomycos?s or	350022

	dracuncul* or echinococcos?s or ectoparasitic infestation* or ectoparasitos?s or egyptian	
	ophthalmia or eumycetoma or filarial elephantias?s or filariose or filiariasis or frambesia	
	or guinea worm disease* or hansen* disease* or helminthias?s or hydatid cysts or	
	hydatidos?s or hydrophobia or kalazar or kala azar or katayama fever or leishmani* or	
	leprae or leepre or leprosies or leprosy or lymphatic filarias?s or lyssa or lyssas or madura	
	foot or maduromycosis or malare or malaria or malayi elephantias?s or malayi filarias?s	
	or myceetome or mycetoma or mycobacterium ulcerans or nagana or neurocysticercos?s	
	or neuroschistosomias?s or onchocercias?s or onchocerca volvulus or onchocercose or	
	oriental sore or plasmodium falciparum or paludisme or rabies or raby or river blindness	
	or sarcoptic mange or scabies or schistosomias?s or schistosomal myel* or snakebite* or	
	snake bite* or snake envenoming or taenia* or taenias?s or teeniase or trachoma* or	
	treponema pallidum or treponematos?s or trypanosomiase or trypanosoma or	
	trypanosomiasis or ulceere or ulcer disease* or wuchereria bancrofti or yaw or yaws or	
	zazzabin cizon sauro).ti,ab,kf.	
37	or/12-36	543044
37	0712-50	545044
38	7 and 11 and 37	1064
39	(animals not humans).sh.	5062487
40	38 not 39	967
41	limit 40 to yr="2000 -Current"	692

3. Tuberculosis

Database(s): Ovid MEDLINE(R) ALL 1946 to February 21, 2023 Search Strategy:		
#	Searches	Results
1	exp Human Migration/	27721
2	exp "Emigrants and Immigrants"/	15365
3	"Transients and Migrants"/	14005
4	Refugees/	12901
5	Refugee Camps/	288
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	573334
7	or/1-6	587109
8	exp Middle East/	159051
9	exp Africa, Northern/	41052
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	317712
11	or/8-10	433998
12	exp Tuberculosis/	204795
13	(koch* disease or koch's disease or tuberculo?s*).ti,ab,kf.	248090
14	(TB adj3 (active or case* or disease* or infection* or latent)).ti,ab,kf.	18905

15	or/12-14	278936
16	7 and 11 and 15	472
17	(animals not humans).sh.	5061699
18	16 not 17	471
19	limit 18 to yr="2000 -Current"	371

4. Vaccine preventable diseases

	Database(s): Ovid MEDLINE(R) ALL 1946 to February 13, 2023 Search Strategy:		
#	Searches	Results	
1	exp Human Migration/	27716	
2	exp "Emigrants and Immigrants"/	15329	
3	"Transients and Migrants"/	13990	
4	Refugees/	12879	
5	Refugee Camps/	286	
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	572839	
7	or/1-6	586614	
8	exp Middle East/	161966	
9	exp Africa, Northern/	41016	
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	317516	
11	or/8-10	436655	
12	exp Vaccines/	272039	
13	exp Immunization/	205597	
14	exp Immunization Programs/	15956	

9

15	(immunostimulation* or immunisation* or immunization* or vaccin* or variolation*).ti,ab,kf.	461660
16	(immunologic* adj2 (sensiti?ation* or stimulation*)).ti,ab,kf.	603
17	Vaccine-Preventable Diseases/	225
18	Cholera/	9238
19	COVID-19/	213155
20	exp Dengue/	15622
21	Diphtheria/	6934
22	exp Hepatitis B/	64040
23	Haemophilus influenzae type b/ or Haemophilus Infections/	8717
24	exp Papillomaviridae/	37470
25	Influenza, Human/	56964
26	Measles/	14748
27	exp Meningococcal Infections/	11761
28	Mumps/	4847
29	Whooping Cough/	9095
30	exp Pneumococcal Infections/	22359
31	exp Poliomyelitis/	20598
32	Rabies/	10830
33	Rubella/	8278
34	Rotavirus Infections/	8644
35	Tetanus/	9782
36	exp Tuberculosis/	204709
37	exp Varicella Zoster Virus Infection/	19758
38	(vaccine preventable adj3 (disease* or illness* or infection*)).ti,ab,kf.	4284

39	(2019 ncov or 2019ncov or breakbone fever or break-bone fever or chickenpox* or chicken pox* or cholera* or cholerae or coqueluche or coronavirus 2 or corona virus disease 2019 or cov2 or cov 2 or covid-19 or covid19 or dengue* or diphtheri* or diphteri* or epidemic parotiti* or german measles or grippe or h1n1 or hav or haemophilus or hbv or hepa or hepatit* or herpesvirus 3 or hepb or hib or hpv or human flu or human papilloma* virus* or hydrophobia or influenza* or koch* disease or lyssa or lyssas or measles or meningit* or meningoco* or mumps or ncov or neisseria meningitidis or neonatal calf diarrhea virus* or new corona virus* or new coronavirus* or novel corona virus* or novel coronavirus* or oreillons or pachymeningiti* or papillomavir* or pertuss* or pfeiffer* bacillus or pneumococcal or pneumoniae or polio* or rabies or rotavirus* or rougeol* or rubella* or rubeol* or sars-cov-2 or sars2 or tdap or tdp or tetani or tetanus* or three day measle* or tuberculos* or varicella or whooping cough*).ti,ab,kf.	1340987
40	or/12-39	1744210
41	7 and 11 and 40	1725
42	(animals not humans).sh.	5059283
43	41 not 42	1682
44	limit 43 to yr="2000 -Current"	1397

5. Maternal and neonatal health

	Database(s): Ovid MEDLINE(R) ALL 1946 to March 23, 2023 Search Strategy:		
#	Searches	Results	
1	exp Human Migration/	27742	
2	exp "Emigrants and Immigrants"/	15413	
3	"Transients and Migrants"/	14073	
4	Refugees/	12961	
5	Refugee Camps/	287	
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	576748	
7	or/1-6	590527	
8	exp Middle East/	159720	
9	exp Africa, Northern/	41145	
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	319881	
11	or/8-10	436540	
12	Maternal Health/ or Maternal Welfare/	8804	
13	exp Maternal Health Services/ or Maternal-Child Health Centers/	58953	
14	Maternal Mortality/ or Maternal Death/	11807	

15	Hypertension, Pregnancy-Induced/ or Pre-Eclampsia/	38475
16	Diabetes, Gestational/	14923
17	Depression, Postpartum/	7293
18	Postpartum Hemorrhage/	8327
19	Anemia, Iron-Deficiency/	11555
20	Pregnancy Complications, Infectious/ or Puerperal Infection/	44906
21	Pregnancy/	978234
22	Gravidity/	1308
23	Pregnancy, High-Risk/ or Pregnancy, Unplanned/ or Pregnancy, Unwanted/	9870
24	Pregnant Women/	13892
25	Pregnancy Trimester, Third/	15768
26	Peripartum Period/	1713
27	exp Delivery, Obstetric/ or Labor, Obstetric/ or Labor Onset/ or exp Labor Presentation/ or "Trial of Labor"/ or Uterine Contraction/	121577
28	Birth Setting/ or Home Childbirth/ or Natural Childbirth/ or Term Birth/	8431
29	Pregnancy Outcome/ or Abortion, Spontaneous/ or Stillbirth/ or Abortion, Incomplete/ or Embryo Loss/ or Abortion, Threatened/	84632
30	Uterine Cervical Incompetence/	1571
31	Obstetric Labor Complications/ or Dystocia/ or Premature Birth/	41246
32	Infant Health/	1251
33	exp Infant Mortality/	31664
34	exp Infant, Low Birth Weight/	38613
35	exp Infant, Premature/	64190
36	(birth* or child bearing or childbearing or childbirth* or expect* mother* or gestation* or gravidit* or multigravidit* or nulligravidit* or obstetric deliver* or pregnan* or primigravidit*).ti,ab,kf.	968064

27	((antenatal* or ante natal* or maternal or perinatal* or peri natal* or peripartum or peri	42045
37	partum or postnatal or post natal or postpartum or post partum or puerperium) adj3 (care or clinic* or healthcare or service*)).ti,ab,kf.	42845
	(abortion* or breech presentation* or dystocia* or embryo death or embryo loss or	
38	embryo resorption or fetal presentation* or incompetent cervi* or labor complication* or labor onset* or labor presentation* or labor trial or obstetric labor or prematurity or "trial	111733
	of labor" or uterine contraction* or uterine cervi* incompetence).ti,ab,kf.	
39	((prematur* or preterm or pre-term) adj3 (baby or babies or child* or deliver* or infant* or neonat* or newborn*)).ti,ab,kf.	95191
40	((low or small) adj3 (birthweight* or birth weight* or gestational age)).ti,ab,kf.	51845
41	(an?emia* or fetal macrosomia* or gestational diabetes or gestational hypertension or postpartum sepsis or pre-eclampsia or preeclampsia or puerperal infection* or	240331
	stillbirth*).ti,ab,kf.	240331
42	((postnatal or post natal or postpartum or post partum) adj2 (depress* or dysphoria* or h?emorrhage*)).ti,ab,kf.	18564
43	((baby or babies or infant* or maternal* or neonat* or newborn* or peri natal* or perinatal*) adj3 (death* or health* or mortalit*)).ti,ab,kf.	135076
44	or/12-43	1658543
45	7 and 11 and 44	1881
46	(animals not humans).sh.	5071308
47	45 not 46	1843
48	limit 47 to yr="2000 -Current"	1308
]

6. Diabetes

	Database(s): Ovid MEDLINE(R) ALL 1946 to May 25, 2023 Search Strategy:		
#	Searches	Results	
1	exp Human Migration/	27778	
2	exp "Emigrants and Immigrants"/	15514	
3	"Transients and Migrants"/	14172	
4	Refugees/	13100	
5	Refugee Camps/	289	
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	583255	
7	or/1-6	597041	
8	exp Middle East/	160899	
9	exp Africa, Northern/	41353	
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	323995	
11	or/8-10	441338	

12	exp Diabetes Mellitus/	504402
13	exp Insulin Resistance/	98730
14	(diabet* or insulin* or metabolic syndrome* or cardiometabolic syndrome* or dysmetabolic syndrome* or reaven syndrome*).ti,ab,kf.	1034882
15	or/12-14	1092851
16	7 and 11 and 15	599
17	(animals not humans).sh.	5090355
18	16 not 17	590
19	limit 18 to yr="2000 -Current"	541


7. Mental health

	Database(s): Ovid MEDLINE(R) ALL 1946 to June 08, 2023 Search Strategy:		
#	Searches	Results	
1	exp Human Migration/	27795	
2	exp "Emigrants and Immigrants"/	15560	
3	"Transients and Migrants"/	14191	
4	Refugees/	13137	
5	Refugee Camps/	291	
6	(alien* or asile or asylum* or (border* adj2 cross*) or (countr* adj3 origin*) or diaspora or displace? or displacement* or emigrant* or emigration or expat? or expatriate? or foreigner* or foreign-born* or foreign background* or foreign population* or immigrant* or immigration or migrant* or migration or naturalized citizen* or new* arriv* or newcomer* or new-comer* or nomad* or non-citizen* or nonnative* or non-native* or nonnational or non-national or nonresident or non-resident* or resettlement* or re- settlement* or refugee* or settler* or squatter* or undocumented worker*).ti,ab,kf.	584365	
7	or/1-6	598153	
8	exp Middle East/	161066	
9	exp Africa, Northern/	41399	
10	(Abu Dhabi or Ajman or Algeri* or Arab* or Bahrain* or Bahreiin* or Dubai or Egypt* or Emirat* or Fujairah or Gaza* or Golf* or Gulf* or Ifriqiya* or Irak* or Iraq* or Jorda* or Jumhuuriiya* or Koweit* or Kuwait* or Kuwayt* or Leban* or Liban* or Liby* or Lubnan* or Maghr* or Maroc* or Maser* or Masr or Misr or MENA or Middle East* or Morocc* or North* Afric* or Oman* or Palestin* or Qatar* or Saudi* or Sharjah or Soudan* or Sudan* or Syria* or Syuri* or Tunis* or Uman* or Umm Al-Quwain or West Bank or Yemen*).ti,ab,kf.	324777	
11	or/8-10	442219	

12	Mental Health/ or exp Mental Disorders/ or Depression/ or Anxiety/ or Resilience, Psychological/	1608207
13	(mental adj2 (disorder* or distress or health or ill-being or illbeing or illness* or ill health or illhealth or instabilit* or symptom* or wellbeing or well-being or wellness)).ti,ab,kf.	299115
14	((psychiatric or psychologic*) adj3 (disorder* or distress or ill-being or illbeing or ill health or illhealth or illness* or problem* or resilienc* or symptom*)).ti,ab,kf.	141346
15	((drug* or heroin or inhalant* or marijuana or morphine or opium or substance*) adj3 (abuse* or addict* or dependenc* or habituation*)).ti,ab,kf.	91981
16	(alcoholic intoxication* or alcoholic psychos* or alcoholism or alcohol withdrawal delirium or binge drinking or opiate overdose or substance-induced psychos*).ti,ab,kf.	39664
17	((alcoholic korsakoff or asperger* or battered child or capgras or creutzfeldt-jakob or female athlete triad or jet lag or kleine-levin or kluver-bucy or munchausen or neonatal abstinence or night eating or restless legs or rumination or substance withdrawal or tourette*) adj3 syndrome*).ti,ab,kf.	16164
18	((adjustment or affective or alcohol-related or amphetamine-related or attention deficit or auditory perceptual or autistic or autism or bipolar or body dysmorphic or child behavio?r* or (pervasive adj2 development*) or cocaine-related or cognition or combat or communication or conduct or consciousness or excessive somnolence or disruptive behavio?r* or dissociative or "drug use" or eating or elimination or factitious or feeding or gender or hoarding or hyperactivity or impulse control or mood or motor or motor skill* or narcotic-related or neurocognitive or neurodevelopmental or neurotic or obsessive- compulsive or opioid-related or panic or paranoid or paraphilic or personality or phobic or psychotic or sexual or sleep* or sleep wake or somatoform or stress* or substance- related or tic or "tobacco use" or trauma) adj3 disorder*).ti,ab,kf.	346123
19	(agoraphobia or alzheimer disease or amnesia or anorexia nervosa or anxiety or bulimia nervosa or cataplexy or chemotherapy-related cognitive impairment or cognitive dysfunction* or delirium or delusional parasitosis or dementia* or depression* or developmental disabilit* or diabulimia or "diffuse neurofibrillary tangles with calcification" or diurnal enuresis or dyscalculia or dyslexia or dyspareunia or dyssomnia* or emergence delirium or encopresis or enuresis or erectile dysfunction or exhibitionism or firesetting behavior* or food addict* or frontotemporal lobar degeneration or	1001530

	gambling or gender dysphoria* or globus sensation or historical trauma* or huntington	
	disease or hypochondriasis or hysteria* or idiopathic hypersomnia or intellectual	
	disabilit* or kinesiophobia* or learning disabilit* or lewy body disease or masochism or	
	morgellons disease or mutism or narcolepsy or neurasthenia or neurocirculatory asthenia	
	or neurosis or neuroses or night terror* or nocturnal enuresis or nocturnal paroxysmal	
	dystonia or orthorexia nervosa or parasomnia* or pedophilia or phencyclidine abuse* or	
	pica or "pick disease of the brain" or postoperative cognitive complication* or premature	
	ejaculation or primary progressive aphasia or primary progressive nonfluent aphasia* or	
	psychiatric fetishism or psychological sexual dysfunction* or psychological trauma* or	
	pure alexia or "relative energy deficiency in sport" or rem sleep parasomnia* or sadism or	
	schizophrenia or sexual trauma* or sleep bruxism or sleep deprivation* or sleep paralysis	
	or sluggish cognitive tempo or social phobia* or somnambulism or transvestism or	
	trichotillomania or vaginismus or voyeurism or wernicke encephalopathy).ti,ab,kf.	
20	or/12-19	2205440
21	7 and 11 and 20	2636
22	(animals not humans).sh.	5094204
23	21 not 22	2629
24	limit 23 to yr="2000 -Current"	2326

PRISMA study flow diagram



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: <u>http://www.prisma-statement.org/</u>